美国东南部IgA肾病患者预期寿命显著缩短
INTRODUCTION: Although end-stage renal disease (ESRD) and surrogate markers for renal dysfunction are frequently used as outcome markers for IgA nephropathy, the clinical course after reaching ESRD is not well documented.…
要点
- IgA肾病患者预期寿命较一般人群缩短10.1年
- 多数患者诊断时已存在肾功能下降
核心结论
- 美国东南部IgA肾病患者预期寿命显著缩短,较预期减少10.1年。
主要发现
- 诊断时中位年龄36.9岁,69%为男性,95%为白人,仅46%的患者估算肾小球滤过率大于60 ml/min per 1.73 m2。
- 平均随访19.3年,132例(53%)进展至终末期肾病,97例(39%)死亡。
- 死亡中位观察年龄为65.7岁,预期中位死亡年龄为75.8岁,预期寿命缩短10.1年。
临床怎么用
- 对IgA肾病患者应重视长期随访和肾脏保护,尤其关注进展至终末期肾病后的生存风险。
局限性
- 研究人群以男性白人为主,结果外推需谨慎。
- 为单中心或区域队列回顾性分析,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Although end-stage renal disease (ESRD) and surrogate markers for renal dysfunction are frequently used as outcome markers for IgA nephropathy, the clinical course after reaching ESRD is not well documented. This study examined outcomes of progression to ESRD and age at death in a cohort of adults with IgA nephropathy with a long duration of follow-up. METHODS: Patient and kidney survival of 251 adult patients with IgA nephropathy from the southeastern United States diagnosed between January 1, 1976 and December 31, 2005 were analyzed. RESULTS: Median age at diagnosis was 36.9 years. Most patients were men (69%) and Caucasian (95%). Only 46% had an estimated glomerular filtration rate >60 ml/min per 1.73 m2 at diagnosis. Mean follow-up time from time of diagnostic biopsy to death or end of study was 19.3 years. Of 251 patients, 132 (53%) progressed to ESRD and 97 (39%) died. Life expectancy was reduced by 10.1 years, with a median observed age of death at 65.7 years and a median expected age at death of 75.8 years. Eighty-three percent of the deaths occurred after progression to ESRD. CONCLUSION: Life expectancy is substantially reduced for patients diagnosed with IgA nephropathy in the southeastern United States.
引用
- Hastings MC, Bursac Z, Julian BA, et al. Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy. Kidney Int Rep. 2017. PMID: 29340319. doi:10.1016/j.ekir.2017.08.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。